Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund cut its stake in shares of Glaukos Corporation (NYSE:GKOS) by 86.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,174 shares of the medical instruments supplier’s stock after selling 335,727 shares during the quarter. New York State Common Retirement Fund owned approximately 0.09% of Glaukos worth $4,255,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. AlphaQuest LLC boosted its position in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares during the period. Smartleaf Asset Management LLC lifted its stake in Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Glaukos by 909.7% during the second quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 1,128 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Glaukos by 4,970.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,724 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 1,690 shares during the last quarter. Finally, M&T Bank Corp acquired a new stake in shares of Glaukos in the 2nd quarter worth about $203,000. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on GKOS shares. Piper Sandler reissued an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, January 14th. Truist Financial lifted their price target on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Stifel Nicolaus increased their price objective on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Citigroup raised their target price on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $138.00 price target on shares of Glaukos in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $132.54.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the sale, the chief financial officer directly owned 50,488 shares of the company’s stock, valued at approximately $5,301,240. This represents a 0.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Marc Stapley sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the transaction, the director owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This trade represents a 28.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 329,655 shares of company stock valued at $37,752,234. 5.80% of the stock is currently owned by insiders.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $112.54 on Friday. The stock has a market cap of $6.46 billion, a price-to-earnings ratio of -73.08 and a beta of 0.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $161.78. The stock’s 50 day moving average price is $114.34 and its 200 day moving average price is $97.45.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.